🎉 M&A multiples are live!
Check it out!

Estrella Immunopharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Estrella Immunopharma and similar public comparables like Pharming, Galapagos, and Benevolent AI.

Estrella Immunopharma Overview

About Estrella Immunopharma

Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.


Founded

2022

HQ

United States of America
Employees

n/a

Website

estrellabio.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$9.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Estrella Immunopharma Financials

Estrella Immunopharma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Estrella Immunopharma achieved revenue of n/a and an EBITDA of -$4.4M.

Estrella Immunopharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Estrella Immunopharma valuation multiples based on analyst estimates

Estrella Immunopharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$7.3M -$4.4M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$11.1M -$7.3M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Estrella Immunopharma Stock Performance

As of April 15, 2025, Estrella Immunopharma's stock price is $1.

Estrella Immunopharma has current market cap of $31.6M, and EV of $9.8M.

See Estrella Immunopharma trading valuation data

Estrella Immunopharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$9.8M $31.6M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Estrella Immunopharma Valuation Multiples

As of April 15, 2025, Estrella Immunopharma has market cap of $31.6M and EV of $9.8M.

Estrella Immunopharma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Estrella Immunopharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Estrella Immunopharma and 10K+ public comps

Estrella Immunopharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $9.8M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E -2.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Estrella Immunopharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Estrella Immunopharma Valuation Multiples

Estrella Immunopharma's NTM/LTM revenue growth is n/a

Estrella Immunopharma's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Estrella Immunopharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Estrella Immunopharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Estrella Immunopharma and other 10K+ public comps

Estrella Immunopharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -39% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Estrella Immunopharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Estrella Immunopharma M&A and Investment Activity

Estrella Immunopharma acquired  XXX companies to date.

Last acquisition by Estrella Immunopharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Estrella Immunopharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Estrella Immunopharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Estrella Immunopharma

When was Estrella Immunopharma founded? Estrella Immunopharma was founded in 2022.
Where is Estrella Immunopharma headquartered? Estrella Immunopharma is headquartered in United States of America.
Who is the CEO of Estrella Immunopharma? Estrella Immunopharma's CEO is Dr. Cheng Liu, PhD.
Is Estrella Immunopharma publicy listed? Yes, Estrella Immunopharma is a public company listed on NAS.
What is the stock symbol of Estrella Immunopharma? Estrella Immunopharma trades under ESLA ticker.
When did Estrella Immunopharma go public? Estrella Immunopharma went public in 2023.
Who are competitors of Estrella Immunopharma? Similar companies to Estrella Immunopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Estrella Immunopharma? Estrella Immunopharma's current market cap is $31.6M
Is Estrella Immunopharma profitable? Yes, Estrella Immunopharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.